poisar

Stocks · News reference

European Regulator Validates Pfizer and Valneva's Lyme Disease Vaccine Application

Vandana Singh

Valneva (VALN) stock surges after EMA validates MAA for Lyme disease vaccine candidate developed with Pfizer (PFE). Phase 3 trial showed efficacy and no safety concerns, pending regulatory approval.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

PFEVALN
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  2. Delveinsight

    Global Dermatological Therapeutics Market to Reach USD 97 Billion by 2034 | DelveInsight

    The global dermatological therapeutics market is projected to grow from USD 43 billion in 2025 to USD 97 billion by 2034, with a CAGR of approximately 10%. Growth is driven by rising prevalence of chronic skin disorders, adoption of biologics and JAK inhibitors, increased healthcare spending, and growing awareness of skin health. North America leads the market with 46% share, while Asia-Pacific is expected to register the fastest growth.

    ABBVLLYJNJNVSBMY

  3. Pfizer Divests Stake in ViiV Healthcare

    Pfizer has exited its equity holding in the HIV-focused joint venture ViiV Healthcare, receiving $1.875 billion as part of a restructuring transaction.

    PFE
  5. Benzinga Insights

    Full Transcript: Valneva Q2 2026 Earnings Call

    Valneva (NASDAQ:VALN) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive financial data and

    VALN